Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/06/03 21:01:42」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

  • Hemodynamic Effects of L-threo-3,4-dihydroxyphenylserine (droxidopa) in Hypotensive Individuals with Spinal Cord Injury.
  • Wecht JM, Rosado-Rivera D, Weir JP, Ivan A, Yen C, Bauman WA.SourceThe Center of Excellence, James J. Peters VAMC, Bronx, NY; Medical Service, James J. Peters VAMC, Bronx, NY; Department of Medicine, , The Mount Sinai School of Medicine, New York, NY; Department of Rehabilitation Medicine, The Mount Sinai School of Medicine, New York, NY. Electronic address: JM.Wecht@va.gov.
  • Archives of physical medicine and rehabilitation.Arch Phys Med Rehabil.2013 Apr 18. pii: S0003-9993(13)00305-5. doi: 10.1016/j.apmr.2013.03.028. [Epub ahead of print]
  • OBJECTIVES: To determine the effect of escalating dose of droxidopa [100 mg, 200 mg, and 400 mg] compared to placebo on seated blood pressure (BP) in hypotensive individuals with SCI. Secondarily we aimed to determine the effect of droxidopa on: 1) supine BP and heart rate (HR), 2) the change in BP
  • PMID 23602882
  • Emerging drugs for autonomic dysfunction in Parkinson's disease.
  • Perez-Lloret S, Rey MV, Pavy-Le Traon A, Rascol O.SourceUniversity of Toulouse III, University Hospital, Department of Clinical Pharmacology and Neuroscience, Toulouse, France. splloret@fleni.org.ar
  • Expert opinion on emerging drugs.Expert Opin Emerg Drugs.2013 Mar;18(1):39-53. doi: 10.1517/14728214.2013.766168. Epub 2013 Feb 1.
  • INTRODUCTION: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson's disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical
  • PMID 23373820
  • L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model.
  • Donsante A, Sullivan P, Goldstein DS, Brinster LR, Kaler SG.SourceUnit on Human Copper Metabolism, Molecular Medicine Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Rockville, MD 20892-1853, USA.
  • Annals of neurology.Ann Neurol.2013 Feb;73(2):259-65. doi: 10.1002/ana.23787. Epub 2012 Dec 7.
  • OBJECTIVE: Menkes disease is a lethal neurodegenerative disorder of infancy caused by mutations in a copper-transporting adenosine triphosphatase gene, ATP7A. Among its multiple cellular tasks, ATP7A transfers copper to dopamine beta hydroxylase (DBH) within the lumen of the Golgi network or secreto
  • PMID 23224983

Japanese Journal

  • Industrial Info. ドプスOD錠の開発 : 新規口腔内崩壊錠技術SUITAB-MAXの適用
  • 仰臥位高血圧・立位低血圧を伴う糖尿病性腎症血液透析患者の血圧コントロール
  • 田中 勝喜,西口 健介,高折 光司 [他],村上 徹,岸本 聡子,玉置 佐奈美,井ノ口 眞澄美,左海 佳奈子,門脇 勧,織田 浩彰,御厨 亮子,桑原 隆
  • 日本透析医学会雑誌 = Journal of Japanese Society for Dialysis Therapy 44(5), 449-453, 2011-05-28
  • 67歳,女性.糖尿病性腎症による血液透析歴16年.週3回3.5時間の維持透析で,体重増加は基本体重(40.2 kg)の約4%である.起床時の血圧は190/90 mmHg,透析前座位血圧120/60 mmHg,透析開始直後(仰臥位)血圧200/90 mmHgにも上昇する.透析終了後起立により血圧が90/50 mmHgまで低下し,当日はほとんど起立できない状況が続いていた.透析中の仰臥位血圧上昇につい …
  • NAID 10029406867
  • 透析患者の敗血症性ショック, 透析時低血圧に対する低用量AVP投与の有効性についての検討
  • 中田 夕香子,田中 杏,川西 智子 [他],越川 真男,田中 敬雄,桑原 隆
  • 日本透析医学会雑誌 = Journal of Japanese Society for Dialysis Therapy 41(11), 779-784, 2008-11-28
  • カテコラミン抵抗性の敗血症性ショックや心原性ショックのみならず,透析時低血圧においても低用量arginine vasopressin(AVP)持続投与を行うことで循環動態の安定を図ることができるとの報告がある.今回われわれは,敗血症を合併した維持血液透析(hemodialysis:HD)患者5例(男性4例,女性1例,平均67.6歳(55~73歳)),敗血症を合併した慢性腎不全急性増悪のため持続的血 …
  • NAID 10023974387

Related Links

L-DOPS (L-threo-dihydroxyphenylserine; Droxidopa; SM-5688) is a psychoactive drug and synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).
ドロキシドパ(Droxidopa)の検索ならお薬検索QLife(キューライフ)。お医者さんが処方 する処方薬と、薬局で買える市販薬(OTC)、の効果と副作用、写真、添付文書、保管 方法等を掲載。商品名だけでなく一般名や剤形、色などからも検索可能。

Related Pictures

Droxidopa (3,4-Dihidroxifenilserina) synthesis of droxidopa - Google PatentsDroxidopa CAS# 23651-95-8 API Supplier droxidopaDroxidopa – WikipediaChelsea Therapeutics International, Ltd




antiparkinson agent, antiparkinsonism drug












  [★] 3,4-スレオジヒドロキシフェニルセリン